J Korean Med Assoc.  2022 Jul;65(7):430-439. 10.5124/jkma.2022.65.7.430.

Reperfusion therapy in acute ischemic stroke

  • 1Department of Neurology, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea
  • 2Department of Neurology, Hallym University Kangdong Sacred Heart Hospital, Seoul, Korea


Until mid-2010, intravenous thrombolysis remains the only reperfusion therapy for acute ischemic stroke. In 2015, the five pivotal endovascular recanalization therapy (ERT) trials demonstrated that ERT improved the prognosis of acute ischemic stroke with large artery occlusion within 6 hours after onset. Currently, ERT has been established as a crucial acute ischemic stroke treatment option. The prognosis of acute ischemic stroke is known to be time-dependent. Several studies addressed that ERT expands the time window for reperfusion therapy; thereby, improving prognosis.
Current Concepts
Recent randomized clinical trials revealed that ERT improved the outcome in patients even within the late time window of up to 24 hours of stroke onset. The trials enrolled participants who had target mismatch, defined as either clinical-core or perfusion-core mismatch, which prompted an update of the national guidelines in several countries. To select the patients with stroke who were eligible for ERT, advanced imaging tools could be recommended.
Discussion and Conclusion
According to the updated ERT guidelines, stroke centers were recommended to establish an appropriate imaging protocol and strategy for patients with acute ischemic stroke who were within the late time window. Additionally, if ERT is further practiced nationally, more manpower and infrastructure for patients with stroke should be supported at the stroke center.


Ischemic stroke; Reperfusion; Thrombolytic therapy; Endovascular procedures; Thrombectomy; 허혈뇌졸중; 재관류; 혈전용해치료; 혈관내시술; 혈전제거
Full Text Links
  • JKMA
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr